Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

dementia Additional studies are needed to determine whether anemia itself is a risk factor for dementia in the CKD population. Anemia in patients with chronic kidney disease (CKD) portends an ...

The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have ...

In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists in the U.S. began prescribing ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

daily multivitamin does not reduce the risks of cvd in men Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

We observed that anemia and chronic kidney disease are two frequent conditions among stroke patients. Anemia was independently associated with a decreased one-year survival. Although GFR was ...

Akebia (AKBA) announced that after meeting with the FDA it has not come to alignment on a path forward for the design of the VALOR clinical trial ...

Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...

Akebia Therapeutics ( (AKBA) ) just unveiled an announcement. On October 28, 2025, Akebia Therapeutics announced that it will not proceed with the VALOR clinical trial for vadadustat, intended to ...